These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 16650196

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M, Ruschitzka F.
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
    Hennekens CH, Borzak S.
    J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):41-50. PubMed ID: 18287589
    [Abstract] [Full Text] [Related]

  • 6. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD.
    Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
    [Abstract] [Full Text] [Related]

  • 7. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ, Stillman MT.
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?
    Spektor G, Fuster V.
    Nat Clin Pract Cardiovasc Med; 2005 Jun; 2(6):290-300. PubMed ID: 16265533
    [Abstract] [Full Text] [Related]

  • 14. The pharmacology of selective inhibition of COX-2.
    Grosser T.
    Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF, Buchanan WW.
    Inflammopharmacology; 2005 Oct; 13(4):343-70. PubMed ID: 16354389
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular hazard and non-steroidal anti-inflammatory drugs.
    Wang D, Wang M, Cheng Y, Fitzgerald GA.
    Curr Opin Pharmacol; 2005 Apr; 5(2):204-10. PubMed ID: 15780832
    [Abstract] [Full Text] [Related]

  • 20. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.